Association of Metastasis with Clinicopathological Data in Mexican Patients with Osteosarcoma, Giant Cell Tumor of Bone and Chondrosarcoma

  • Estrada-Villaseor, E (Department of Pathology, National Institute of Rehabilitation) ;
  • Escamilla-Uribe, R (Division of Neuroscience, National Institute of Rehabilitation) ;
  • De la Garza-Montano, P (Division of Neuroscience, National Institute of Rehabilitation) ;
  • Dominguez-Rubio, R (Superior Medicine School of National Polytechnic Institute) ;
  • Martinez-Lopez, V (Unit of Tissue Engineering, Institute of Rehabilitation) ;
  • Avila-Luna, A (Division of Neuroscience, National Institute of Rehabilitation) ;
  • Alfaro-Rodriguez, A (Division of Neuroscience, National Institute of Rehabilitation) ;
  • Ruvalcaba-Paredes, EK (Cell Therapy and Regenerative Medicine, Institute of Rehabilitation) ;
  • Garciadiego-Cazares, D (Unit of Tissue Engineering, Institute of Rehabilitation) ;
  • Bandala, C (Division of Neuroscience, National Institute of Rehabilitation)
  • Published : 2015.12.03


Background: Bone tumors are neoplasias with a high overall mortality; one of the main factors that reduce survival is their high capacity to develop metastases. It has been reported that finding lung metastases at diagnosis of osteosarcoma (OS), chondrosarcoma (CS) and giant cell tumor of bone (GCTb) is quite common. In this study, we inquire the relationship of metastases caused by these tumors with different clinical and pathological aspects, in order to guide medical personnel in the diagnosis and opportune treatment of metastases or micro metastases. Materials and Methods: We collected data of 384 patients with clinical, radiological and histopathological diagnosis of OS, GCTb and CS that attended the National Rehabilitation Institute (INR) during 2006 to 2014. Chi-square and Fisher's exact tests were performed for data analysis. Results: In the three tumor types, the presence of metastases at diagnosis was variable (p=0.0001). Frequency of metastases was 36.7%, 31.7% and 13.2% for OS, CS and GCTb respectively. The average age had no significant difference (p>0.05) in relation to metastases, even so, patients with OS and GCTb and metastases, were older while patients with CS and metastases were younger, in comparison to patients without metastases. Males had a higher frequency of metastases (68.2%, p = 0.09) in contrast to CS and GCTb, in which the metastases was more frequent in women with 51.9% (p = 0.44) and 57.9% (p = 0.56) respectively. Broadly, metastasis was associated with primary tumors located in the femur (44.4%), followed by the tibia (15.6%); metastases was more frequent when primary tumor of GCTb and OS were in the same bones, but were located in the hip (26.3%) for CS. Conclusions: The frequency of metastases in OS, GCTb and CS is high in our population and is determined by different clinicopathological variables related to the kind of tumor. Further studies are needed in order to evaluate metastases subsequent to diagnosis and associations with survival and clinicopathological factors, as well as to determine the sensitivity and specificity of current methods of detection.


Giant cell tumor of bone;chondrosarcoma;osteosarcoma;metastasis


  1. Arnold RT, van Holsbeeck MT, Mayer TG, Mott MP, Koch SR (2011). Necrotic giant cell tumor of bone manifesting with pathologic fracture. Radio Graphics, 31, 93-8.
  2. Azarpira N, Javadi F, Safarian A (2015). Giant cell tumor of the thoracic vertebra: a case report. Neurosurg Q, 25, 264-6.
  3. Baena-Ocampo L del C, Ramirez-Perez E, Linares-Gonzalez LM, Delgado-Chavez R (2009). Epidemiology of bone tumors in Mexico City: retrospective clinicopathologic study of 566 patients at a referral institution. Ann Diagn Pathol, 13, 16-21.
  4. Choeyprasert W, Pakakasama S, Sirachainan N, et al (2014). Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. Asian Pac J Cancer Prev, 15, 9823-9.
  5. Chow WA (2007). Update on chondrosarcomas. Curr Opin Oncol, 19, 371-6.
  6. Cintra FF, Etchebehere M, Goncalves JC, Cassone AE, Amstalden EM (2014). Vascular pattern in enchondroma and chondrosarcoma: clinical and immunohistologic study. Appl Immunohistochem Mol Morphol, 22, 600-5.
  7. Cortes-Rodriguez R, Castaneda-Pichardo G, Tercero-Quintanilla G (2010). Guia de diagnostico y tratamiento para pacientes pediatricos con osteosarcoma. Inv Mat Inf, 2, 60-6.
  8. De la Garza NJM, Ceccopieri CA, Cruz Ortiz H, Diaz Rodriguez LR, Martinez Macias R (1999) Tumor de celulas gigantes de hueso. Aspectos generales de 11 casos. Rev Med Hosp Gen Mex, 62, 240-4.
  9. Ferguson WS, Goorin AM (2001). Current treatment of osteosarcoma. Cancer Invest, 19, 292.
  10. Gelderblom H, Hogendoorn PC, Dijkstra SD, et al (2008). The clinical approach towards chondrosarcoma. Oncologist, 13, 320-9.
  11. Huang YJ, He AN, Sun YJ, et al (2015). Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study. Asian Pac J Cancer Prev, 16, 2391-5.
  12. Joo MW, Shin SH, Kang YK, et al (2015). Osteosarcoma in asian populations over the age of 40 years: a multicenter study. Ann Surg Oncol, 13.
  13. Li YY, Jiang XM, Dong YG, Xu G, Ma YB (2014). Ifosfamidecontaining regimens for treating patients with osteosarcomas. Asian Pac J Cancer Prev, 15, 9763-6.
  14. Linares-Gonzalez M, Rico Martinez G, Dominguez-Herandez VM, et al (2014). Tratamiento y reconstruccion en tumores oseos del humero con protesis no convencional tipo RIMAG. Acta Ortop Mex, 28, 3-11.
  15. Liu X, Min L, Chen G, Hong S, Tu C (2015). Bony metastases following complete resection of periosteal chondrosarcoma. World J Surg Oncol, 13, 121.
  16. Llamas-Duran LF, Tarango-Martinez VM, Fuentes-Sermeno IL, Fajardo-Barajas D (2011). Tumor de Celulas Gigantes del hueso de localizacion infrecuente. Med Cutan Iber Lat Am, 39, 234-7.
  17. Martinez-Cedillo J (2012). Osteosarcoma. Success of adjuvant chemotherapy. After 25 years. Is there something new? GAMO, 11, 293-5.
  18. Muheremu A, Niu X (2014). Pulmonary metastasis of giant cells tumor of bones. World J Surg Oncol, 12, 261.
  19. Murphey MD, Nomikos GC, Flemming DJ, et al (2001). From the archives of AFIP. imaging of giant cell tumor and giant cell reparative granuloma of bone: radiologic-pathologic correlation. Radiographics, 21, 1283-309.
  20. Muscolo DL, Farfalli G, Aponte-Tinao LA, Ayersa MA (2009). Actualizacion en osteosarcoma. Rev Asoc Argent Ortop Traumatol, 74, 85-1.
  21. Niembro Zuniga AM, Castellanos Toledo A, Gutierrez Castrellon P, et al (2005). Resultados de ocho anos en el tratamiento de Osteosarcoma. experiencia en el instituto nacional de pediatria, mexico. Gamo, 4, 34-0.
  22. Niu X, Zhang Q, Hao L, et al (2012) Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution. J Bone Joint Surg Am, 94, 461-7.
  23. Niu F, Zhao S, Xu CY, et al (2014). Identification and functional analysis of differentially expressed genes related to metastatic Osteosarcoma. Asian Pac J Cancer Prev, 15, 10797-1.
  24. Pereira HM, Marchiori E, Severo A (2014). Magnetic resonance imaging aspects of giant-cell tumours of bone. J Med Imaging Radiat Oncol, 58, 674-8.
  25. Picci P (2007). Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Diseases, 2, 6.
  26. Present D, Bertoni F, Hudson T, Enneking WF (1986). The correlation between the radiologic staging studies and histopathologic findings in aggressive stage 3 giant cell tumor of bone. Cancer, 57, 237-4.<237::AID-CNCR2820570209>3.0.CO;2-8
  27. Puri A, Agarwal MG, Shah M, et al (2007). Giant cell tumor of bone in children and adolescents. J Pediatr Orthop, 27, 635-9.
  28. Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ (2013). Giant cell tumor of bone. J Am Acad Orthop Surg, 21, 118-6.
  29. Ries LA, Smith MA, Gurney JG, et al (1999). Cancer incidence and survival among children and adolescents: united states seer program 1975-1995, national cancer institute, SEER program. NIH Pub. Bethesda, MD. 99-9.
  30. Sanchez-Torres LJ, Flores Flores A, Santos Hernandez M (2012). Tumor oseo de celulas gigantes en pacientes de menos de 20 anos de edad. Rev Mex Ortop Ped, 14, 26-0.
  31. Turcotte RE (2006). Giant cell tumor of bone. Orthop Clin North Am, 37, 35-1.
  32. Uribe-Rosales D, Carranza-Arellano C, Ramos-Moreno R (2014). Aspectos biologicos y clinicos para comprender mejor al osteosarcoma. Inv Disc, 3, 33-0.
  33. Weber KL, Pring ME, Sim FH (2002). Treatment and outcome of recurrent pelvic chondrosarcoma. Clin Orthop Relat Res, 397, 19-8.
  34. Yang ZM, Tao HM, Ye ZM, et al (2012). Multivariate analysis of the prognosis of 37 chondrosarcoma patients. Asian Pac J Cancer Prev, 13, 1171-6.
  35. Zhu L, McManus MM, Hughes DP (2013). Understanding the biology of bone sarcoma from early initiating events through late events in metastasis and disease progression. Front Oncol, 17, 1-17.